TVTX
NASDAQ · Biotechnology
Travere Therapeutics Inc
$26.84
-0.88 (-3.17%)
Financial Highlights (FY 2026)
Revenue
260.45M
Net Income
-359,164,101
Gross Margin
96.7%
Profit Margin
-137.9%
Rev Growth
+0.8%
D/E Ratio
6.42
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 96.7% | 96.7% | 53.7% | 53.7% |
| Operating Margin | -138.9% | -125.0% | 9.4% | 7.8% |
| Profit Margin | -137.9% | -131.0% | 9.6% | 8.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 260.45M | 258.33M | 873.79M | 704.19M |
| Gross Profit | 251.81M | 249.76M | 469.44M | 378.33M |
| Operating Income | -361,717,449 | -322,897,940 | 81.83M | 54.90M |
| Net Income | -359,164,101 | -320,618,618 | 83.63M | 59.82M |
| Gross Margin | 96.7% | 96.7% | 53.7% | 53.7% |
| Operating Margin | -138.9% | -125.0% | 9.4% | 7.8% |
| Profit Margin | -137.9% | -131.0% | 9.6% | 8.5% |
| Rev Growth | +0.8% | +0.8% | +12.5% | -3.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.13B | 1.13B | 191.77M | 223.22M |
| Total Equity | 176.77M | 176.77M | 1.35B | 1.30B |
| D/E Ratio | 6.42 | 6.42 | 0.14 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -318,796,802 | -300,393,733 | 111.75M | 89.10M |
| Free Cash Flow | — | — | 68.75M | 73.37M |